Australia has new national guidelines for the early detection of prostate cancer. They were published on 18 May 2026 by the Prostate Cancer Foundation of Australia and approved by the National Health and Medical Research Council. They replace guidelines that had stood since 2016.
Ten years is a long time in medicine. A lot has changed, and most of it is good news.
The short version
If you are a man aged 50 to 69, testing is now more strongly supported than it was a decade ago. Long term data from the European screening trials show fewer men dying of prostate cancer when testing is offered. That evidence has matured, and the guidelines have moved with it.
If you have a family history or certain genetic risks, the conversation should start earlier, at 45.
And if something is picked up, the pathway from an abnormal result to a diagnosis is safer than it used to be. Fewer men now go straight to a biopsy. Fewer men with slow growing cancer go straight to surgery.
What the new guidelines actually recommend
The headline points, in plain terms.
Age 50 to 69. If you decide to be tested after talking it through with your doctor, a PSA blood test every two years is the recommended approach. A result of 3.0 or above is repeated within one to three months. If it stays up, you get referred for further investigation.
Age 45 to 49. Routine testing is not recommended for men at ordinary risk. But if you are interested in your prostate health, a single baseline PSA is reasonable. If it comes back under 1.0, nothing further is needed until you turn 50. That one test tells us a great deal about your risk for the next decade.
Age 70 and over. Testing is still on the table, but it becomes a judgement call. Your doctor should weigh up your general health, your other conditions and what matters to you. The action threshold is higher at 5.5. As a rule, testing is only offered where life expectancy is greater than seven years.
If you are at higher risk. Start the conversation at 45, test every two years, and the thresholds for acting are deliberately lower.
Aboriginal and Torres Strait Islander men. The testing thresholds are the same as for everyone else. The guidelines call for testing to be built into the annual health assessment, and for better use of telehealth, outreach and point of care testing so that access is not the barrier.
Who counts as higher risk
The old guidelines asked doctors to calculate how many times above average your risk was. The new ones simplify it. You are considered higher risk if your risk of significant prostate cancer or of dying from it is at least double the average Australian man's. That includes:
A brother diagnosed with prostate cancer
A father diagnosed before the age of 65
Two or more second degree relatives, such as uncles or grandfathers, who died of prostate cancer
Black men of sub-Saharan African ancestry
Men carrying a BRCA2 gene mutation
Family cancer syndromes such as hereditary breast and ovarian cancer, and Lynch syndrome, also raise the risk.
If any of that describes you, it is worth raising with your GP well before you turn 50.
The finger test is no longer routine
This one tends to get attention, so it is worth being clear.
The guidelines now advise against the digital rectal examination as a routine add on to PSA testing in general practice. The evidence does not show it adds enough in that setting to justify it.
It has not disappeared. It remains part of the specialist assessment if you are referred on. But it is no longer the price of admission for a PSA test in your GP's rooms.
An abnormal PSA does not mean a biopsy
This is the single biggest change since 2016, and it is the reason testing carries less downside than it used to.
If your PSA is confirmed as elevated, the next step is now an MRI scan of the prostate, not a biopsy. The scan sorts out who genuinely needs a biopsy and who does not. In practice it avoids up to half of the biopsies that would previously have been done, while still reliably finding the cancers that matter.
If a biopsy is needed, it is done through the skin rather than through the bowel wall, which carries a much lower risk of serious infection.
A diagnosis does not automatically mean treatment
For men with low risk prostate cancer, active surveillance is now the preferred approach. That means careful monitoring with regular PSA tests, periodic scans and repeat biopsies at set intervals, rather than immediate surgery or radiotherapy.
More than 80 per cent of Australian men with low risk prostate cancer now choose this path. It spares them the incontinence and sexual side effects of treatment they may never have needed, without giving up the option of curative treatment if things change.
The guidelines are also explicit that a rising PSA on its own is not a reason to change course.
What this means for you
The old worry about prostate testing was reasonable. Men were told that a PSA test could set off a chain of events, biopsy, diagnosis, treatment, side effects, for a cancer that was never going to trouble them.
That chain has been broken at nearly every link. Better risk assessment at the start. MRI before biopsy in the middle. Active surveillance at the end. The test itself has not changed much. What we do with the result has changed enormously.
The one thing the guidelines will not do is make the decision for you. Every recommendation is framed around an informed discussion with your doctor. You can opt in, opt out, and change your mind at any point.
If you are 50 or over, or 45 with a family history, that conversation is worth booking.
Dr Danny Cai is a GP with 25 years of clinical experience and the Founder and Medical Director of AvaElis Health, a longevity medicine practice in Sydney.
This article is general information and is not a substitute for individual medical advice. If you have questions about prostate cancer testing, discuss them with your own doctor. The full guidelines are published by the Prostate Cancer Foundation of Australia at pcfa.org.au.
